🇺🇸 FDA
Patent

US 12036225

Use of ibezapolstat to promote microbiome health

granted A61KA61K31/522A61K31/5377

Quick answer

US patent 12036225 (Use of ibezapolstat to promote microbiome health) held by Acurx Pharmaceuticals, Inc. expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Acurx Pharmaceuticals, Inc.
Grant date
Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/522, A61K31/5377, A61P, A61P1/00